BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 344 filers reported holding BIO-TECHNE CORP in Q3 2018. The put-call ratio across all filers is 1.17 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $445,000 | +35.3% | 2,180 | -1.9% | 0.14% | +30.0% |
| Q2 2018 | $329,000 | -14.1% | 2,223 | -14.9% | 0.11% | -11.3% |
| Q1 2018 | $383,000 | +7.6% | 2,612 | -5.0% | 0.12% | +25.3% |
| Q4 2017 | $356,000 | +8.9% | 2,749 | +1.8% | 0.10% | +4.2% |
| Q3 2017 | $327,000 | -6.6% | 2,701 | -9.2% | 0.10% | -6.9% |
| Q2 2017 | $350,000 | – | 2,975 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fithian, LLC | 101,020 | $7,494,674 | 15.66% |
| Montanaro Asset Management Ltd | 387,800 | $28,770,882 | 4.47% |
| Brown Capital Management | 3,262,377 | $242,035,750 | 3.62% |
| Sandhill Capital Partners LLC | 501,059 | $37,173,549 | 3.56% |
| STONE RUN CAPITAL, LLC | 89,435 | $6,635,183 | 3.17% |
| DF DENT & CO INC | 2,949,044 | $218,789,610 | 3.08% |
| Ownership Capital B.V. | 2,324,358 | $172,444,120 | 3.03% |
| Jackson Square Partners, LLC | 1,485,067 | $110,177,121 | 2.98% |
| Summit Creek Advisors LLC | 283,412 | $21,026,336 | 2.74% |
| Westwind Capital | 111,666 | $8,284,501 | 2.65% |